Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:50:23 EST Fri 06 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:JNJ - JOHNSON & JOHNSON - https://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z2.0236.00·241.400.1239.63-5.60-2.39,375.22,230,162134,058242.63  243.00  235.93251.705  142.2019:59:3015:5415 min RT 2¢

Recent Trades - Last 10 of 134058
Time ETExPriceChangeVolume
19:59:30Z240.00-5.302
19:56:15Z239.99-5.3125
19:52:58Z239.99-5.312
19:52:43Z239.9988-5.30121
19:51:30Z239.9847-5.31535
19:46:21Z239.80-5.501
19:43:12Z239.95-5.351
19:41:36Z239.95-5.352
19:38:58Z239.9651-5.33498
19:38:58Z239.9651-5.33498

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-05 15:54U:JNJNews ReleaseJohnson & Johnson Announces U.S. FDA Approval of TECVAYLI(TM) plus DARZALEX FASPRO(TM) for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
2026-03-03 08:03U:JNJNews Release/C O R R E C T I O N -- Johnson & Johnson/
2026-03-02 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on First-Quarter Results
2026-02-26 14:30U:JNJNews ReleaseEarly study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
2026-02-24 16:03U:JNJNews ReleaseJohnson & Johnson seeks FDA approval of IMAAVY(TM) (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
2026-02-21 08:00U:JNJNews ReleaseTREMFYA(TM) (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
2026-02-19 17:00U:JNJNews ReleaseRYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
2026-02-18 10:15U:JNJNews ReleaseJohnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
2026-02-18 07:30U:JNJNews ReleaseRYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
2026-02-17 08:00U:JNJNews ReleaseFDA approves RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
2026-02-12 16:45U:JNJSEDAR MD & ASEDAR MD & A
2026-02-12 16:33U:JNJSEDAR Audited Annual Financial StatementsSEDAR Annual Report
2026-02-09 16:16U:JNJNews ReleaseJohnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
2026-02-06 19:00U:JNJNews ReleaseJohnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
2026-02-02 16:34U:JNJNews ReleaseJohnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
2026-01-27 15:49U:JNJNews ReleaseDARZALEX FASPRO(TM)-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
2026-01-27 08:00U:JNJNews ReleaseJohnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
2026-01-21 06:20U:JNJNews ReleaseJohnson & Johnson reports Q4 and Full-Year 2025 results
2026-01-14 16:30U:JNJNews ReleaseTECVAYLI(TM) monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
2026-01-13 08:00U:JNJNews ReleaseJohnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting